Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648254 | 0.91 | KDM1A (0.50) | KDM1AMAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL11828242 | 0.87 | MAPT (0.64) | KDM1AMAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL4267531 | 0.83 | MRGPRX4 (0.63) | KDM1AMAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL9706382 | 0.81 | MAPT (0.58) | KDM1AMAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL3489533 | 0.81 | MAPT (0.58) | KDM1AMAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL30080427 | 0.81 | MAPT (0.58) | KDM1AMAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL2895075 | 0.81 | KDM1A (0.60) | KDM1AMAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL1766157 | 0.80 | NPC1 (0.56) | KDM1AMAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL1766179 | 0.80 | MAPT (0.56) | KDM1AMAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL2896596 | 0.79 | KDM1A (0.59) | KDM1AMAPTL3MBTL1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0624567-B1 | Derivatives of 3-fluorophenol, process for their preparation and their use | CLARIANT GMBH (DE) | 1999-12-08 | — | — | EP | claimed |
| EP-0624567-A2 | Derivatives of 3-fluorophenol, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-17 | — | — | EP | claimed |
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| CN-107660205-B | Heterocyclic compounds as LSD1 inhibitors | 因赛特公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20210186021-A1 | DIAMINOTRIAZINE COMPOUNDS | BASF SE (DE) | 2021-06-24 | — | — | US | disclosed |
| CN-112739687-A | Diaminotriazine compounds | 巴斯夫欧洲公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2020-12-17 | — | — | US | disclosed |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2020-12-17 | — | — | US | disclosed |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| WO-2020058009-A1 | DIAMINOTRIAZINE COMPOUNDS | BASF SE (DE) | 2020-03-26 | — | — | WO | disclosed |
| EP-1478629-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| WO-2003072553-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-0624567-B1 | Derivatives of 3-fluorophenol, process for their preparation and their use | CLARIANT GMBH (DE) | 1999-12-08 | — | — | EP | disclosed |
| EP-0628536-B1 | Process for the preparation of aromatic amines | CLARIANT GMBH (DE) | 1999-07-14 | — | — | EP | disclosed |
| US-5410082-A | Process for preparing amines | CLARIANT GMBH (DE) | 1995-04-25 | — | — | US | disclosed |
| EP-0628536-A2 | Process for the preparation of amines | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0624567-A2 | Derivatives of 3-fluorophenol, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | KDM1A 2/4885MAPT 2861/4885L3MBTL1 550/4885 |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, DOT1L | KDM1A 2/4885MAPT 2861/4885L3MBTL1 550/4885 |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | KDM1A 1528/4885MAPT 4491/4885L3MBTL1 3033/4885 |
| US-20210186021-A1 | DIAMINOTRIAZINE COMPOUNDS | DDT, DAZAP1, DDC | KDM1A 1128/4885MAPT 623/4885L3MBTL1 1726/4885 |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | KDM1A 1528/4885MAPT 4491/4885L3MBTL1 3033/4885 |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | KDM1A 2/4885MAPT 2861/4885L3MBTL1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.